Clinical Trials Directory

Trials / Completed

CompletedNCT00742274

A European Study on Medical Management Versus TAG Device + Medical Management for Acute Uncomplicated Type B Dissection

A Randomized European Study Comparing Endoluminal Stent Grafting and Best Medical Therapy (BMT) to BMT Alone in the Treatment of Acute Uncomplicated Type B Aortic Dissection

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
61 (actual)
Sponsor
W.L.Gore & Associates · Industry
Sex
All
Age
18 Years – 80 Years
Healthy volunteers
Not accepted

Summary

The purpose of this study is to compare endoluminal stent grafting with the GORE TAG device and Best Medical Therapy (BMT) to BMT alone in the treatment of acute uncomplicated type B aortic dissections.

Detailed description

Dissection of the aorta is a medical emergency requiring immediate surgery. Type B dissections are typically treated with surgery or endoluminal therapy when complications such as uncontrollable pain, organ ischemia, or aortic rupture are present. However, the treatment of patients with uncomplicated, acute type B dissections is controversial. Best medical therapy (BMT) is the standard of care in these cases since surgical repair offers no additional survival advantage. However, Endoluminal stent graft therapy with the GORE TAG Thoracic Endoprosthesis (GORE TAG device) may offer distinct advantages as an adjunct to medical therapy for uncomplicated acute type B dissection. The goal of endoluminal stent grafting is to cover the primary entry tear of the dissection to isolate the false lumen from blood flow and induce aortic remodeling.

Conditions

Interventions

TypeNameDescription
DEVICEGore TAG EndoprosthesisImplant Gore TAG device with Best Medical therapy per physician discretion
OTHERBest Medical TherapyBest Medical therapy is regimen of antihypertensive medications used to maintain blood pressure below 125/80 mm/Hg throughout the entire follow-up period. Because BMT is assessed by blood pressure response to medication, specific medication regimens for each patient will differ. The typical regimen consists of 1 to 4 concomitant antihypertensive medications that may include angiotensin converting enzyme (ACE) inhibitors, alpha blockers, beta blockers, calcium channel blockers, diuretics, and/or vasodilators.

Timeline

Start date
2008-08-01
Primary completion
2012-02-01
Completion
2013-10-01
First posted
2008-08-27
Last updated
2013-12-04
Results posted
2013-05-09

Source: ClinicalTrials.gov record NCT00742274. Inclusion in this directory is not an endorsement.